News

Global Tumor Necrosis Factor Receptor Superfamily Member 1A Pipeline Analysis Research Report with Coverage of Leading Players

Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) – Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS). The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 2, 2 and 3 respectively.

Report Source: https://www.themarketreports.com/report/tumor-necrosis-factor-receptor-superfamily-member-1a-tumor-necrosis-factor-receptor-1-or-tumor-necrosis-factor-receptor-type-i-or-p55-or-p60-or-cd120a-or-tnfrsf1a-pipeline-review-h1

Scope

  • The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A targeted therapeutics

Purchase this report at: https://www.themarketreports.com/report/buy-now/1470891

Reasons To Buy

  • Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

  • Baliopharm AG
  • CytImmune Sciences Inc
  • Eyevensys SAS
  • G&E Corp
  • GlaxoSmithKline Plc
  • Inflamalps SA
  • Inmune Bio Inc
  • Philogen SpA
  • Promethera Biosciences SA

Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/1470891